BACKGROUND: To increase the immunosurveillance in HIV infection, we used retroviral vectors expressing CD4-chimeric antigen receptors (CARs) to genetically modify autologous T cells and redirect CTL toward HIV. The CD4 extracellular domain targets envelope and the intracellular signaling domains activate T cells. The maC46 fusion inhibitor binds HIV and blocks viral replication. METHODS: We stimulated rhesus PBMCs with antibodies to CD3/CD28 and cotransduced T cells with CD4-CAR and maC46 vectors. CD4-CAR-transduced T cells were added to Env(+) 293T cells at E:T of 1:1. Killing of target cells was measured as reduced impedance. RESULTS: We observed gene expression in 60-70% of rhesus CD3(+) CD8(+) T cells with the individual vectors and in 35% of the cells with both vectors. CD4-CAR-transduced populations specifically killed Env(+) cells. CONCLUSIONS: In these studies, we showed that designer T cells were redirected to kill Env(+) cells. Control of viremia without HAART would revolutionize treatment for HIV patients.
BACKGROUND: To increase the immunosurveillance in HIV infection, we used retroviral vectors expressing CD4-chimeric antigen receptors (CARs) to genetically modify autologous T cells and redirect CTL toward HIV. The CD4 extracellular domain targets envelope and the intracellular signaling domains activate T cells. The maC46 fusion inhibitor binds HIV and blocks viral replication. METHODS: We stimulated rhesus PBMCs with antibodies to CD3/CD28 and cotransduced T cells with CD4-CAR and maC46 vectors. CD4-CAR-transduced T cells were added to Env(+) 293T cells at E:T of 1:1. Killing of target cells was measured as reduced impedance. RESULTS: We observed gene expression in 60-70% of rhesus CD3(+) CD8(+) T cells with the individual vectors and in 35% of the cells with both vectors. CD4-CAR-transduced populations specifically killed Env(+) cells. CONCLUSIONS: In these studies, we showed that designer T cells were redirected to kill Env(+) cells. Control of viremia without HAART would revolutionize treatment for HIV patients.
Authors: R E Walker; C M Bechtel; V Natarajan; M Baseler; K M Hege; J A Metcalf; R Stevens; A Hazen; R M Blaese; C C Chen; S F Leitman; J Palensky; J Wittes; R T Davey; J Falloon; M A Polis; J A Kovacs; D F Broad; B L Levine; M R Roberts; H Masur; H C Lane Journal: Blood Date: 2000-07-15 Impact factor: 22.113
Authors: Steven G Deeks; Bridget Wagner; Peter A Anton; Ronald T Mitsuyasu; David T Scadden; Christine Huang; Catherine Macken; Douglas D Richman; Cindy Christopherson; Carl H June; Richard Lazar; David F Broad; Sayeh Jalali; Kristen M Hege Journal: Mol Ther Date: 2002-06 Impact factor: 11.454
Authors: Peter C R Emtage; Danielle Clarke; Rosa Gonzalo-Daganzo; Richard P Junghans; Rosa Gonzalo-Dagonzo Journal: J Immunother Date: 2003 Mar-Apr Impact factor: 4.456
Authors: Janine Kimpel; Stephen E Braun; Gang Qiu; Fay Eng Wong; Michelle Conolle; Jörn E Schmitz; Christian Brendel; Laurent M Humeau; Boro Dropulic; John J Rossi; Annemarie Berger; Dorothee von Laer; R Paul Johnson Journal: PLoS One Date: 2010-08-23 Impact factor: 3.240
Authors: Timothy Kute; John R Stehle; David Ornelles; Natalie Walker; Osvaldo Delbono; James P Vaughn Journal: Oncoimmunology Date: 2012-09-01 Impact factor: 8.110
Authors: Stephen E Braun; Xuanling Shi; Gang Qiu; Fay Eng Wong; Pheroze J Joshi; Vinayaka R Prasad; R Paul Johnson Journal: AIDS Res Ther Date: 2007-10-17 Impact factor: 2.250
Authors: Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger Journal: J Virol Date: 2015-04-15 Impact factor: 5.103